GLP-1 Receptor Agonist Violent Behavior Study
This study highlights the GLP-1 receptor agonist psychiatric safety profile, focusing on semaglutide's association with reduced violent behavior. The findings suggest neuropsychiatric benefits beyond metabolic effects. Clinicians should consider these…
France’s Medical Cannabis Trial: 3% Serious Adverse Events in 3,164 Patients Over Three Years
The medical cannabis safety adverse drug reactions study in France tracked 3,164 patients over three years. It found 3% experienced serious adverse drug reactions, mainly neurological, gastrointestinal, and psychiatric. This observational study provides…
Research on cannabis’s brain effects reveals a complex and uncertain picture.
Emerging research on cannabis brain effects reveals a complex and uncertain picture. Clinicians must understand these effects to counsel patients effectively. The evidence highlights both potential cognitive risks and the need for cautious interpretation.
Understanding Cannabis and False Memory Formation
Cannabis false memory formation clinical evidence highlights a significant risk of recalling events that never happened. This phenomenon differs from simple memory impairment and involves active creation of inaccurate memories. Understanding this risk is…